title: Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma.
abstract: More than 1/3 of all non-small cell lung carcinoma (NSCLC) patients present with locally advanced non-metastatic disease. Despite radiation therapy and surgery the survival of these patients remains poor. In an effort to improve upon these results 33 clinical Stage III M0 patients from April 1985 through September 1986 were entered into a Phase II study at Rush-Presbyterian-St. Luke's Medical Center. Treatment included 5-FU by continuous infusion, VP-16, cisplatin and concurrent split course radiation therapy followed by surgical resection when possible. The overall clinical response rate is 74%. Fifty-seven percent of the preoperative group of patients went to surgery with a 100% resectability rate. These patients had a 50% pathologic complete response with no tumor found in the resected specimen. All surgical margins were free of disease and there were no operative deaths. This concurrent combined modality therapy is feasible with the major toxicities being leukopenia, nausea, and vomiting. With an overall median follow-up of 15 months, 36% of the patients remain alive. Overall local control is 71%. Actuarial observed 2 yr. survival is 33% and the median survival is 15 months. Histologic complete response appears to be an early indicator of the efficacy of this treatment regime. With 83% of the resected pathologic complete responders alive without evidence of disease, this preoperative combined modality therapy offers an appealing approach.
authors.affiliation: Dept. of Therapeutic Radiology, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL 60612.
authors.forename: M
authors.initials: M
authors.lastname: Pincus
authors.forename: S
authors.initials: S
authors.lastname: Reddy
authors.forename: M S
authors.initials: MS
authors.lastname: Lee
authors.forename: P
authors.initials: P
authors.lastname: Bonomi
authors.forename: S
authors.initials: S
authors.lastname: Taylor
authors.forename: K
authors.initials: K
authors.lastname: Rowland
authors.forename: L P
authors.initials: LP
authors.lastname: Faber
authors.forename: W
authors.initials: W
authors.lastname: Warren
authors.forename: C F
authors.initials: CF
authors.lastname: Kittle
authors.forename: F R
authors.initials: FR
authors.lastname: Hendrickson
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D005047:Etoposide; D002945:Cisplatin; D005472:Fluorouracil